Cochrane · systematic review · CD009072
Pathogen‐reduced platelets for the prevention of bleeding
Estcourt, LJ, Malouf, R, Hopewell, S, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 4 · 57.1%High 2 · 28.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyPathogen‐reduced platelets versus standard platelets for the prevention of bleeding
Population: thrombocytopenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants with 'any bleeding' event(s) (WHO grade 1 to 4 or equivalent) ‐ Pathogen‐reduced platelets vs standard platelets | RR 1.09 [1.02, 1.15] | 5 studies · 1085 participants | Low Downgraded: inconsistency |
Number of participants with 'clinically significant' bleeding event(s) (WHO grade ≥ 2 or equivalent) ‐ Pathogen‐reduced platelets vs standard platelets | RR 1.1 [0.97, 1.25] | 5 studies · 1392 participants | Moderate |
Number of participants with 'severe' bleeding event(s) (WHO grade ≥ 3 or equivalent) ‐ Pathogen‐reduced platelets vs standard platelets | RR 1.24 [0.76, 2.02] | 6 studies · 1495 participants | Moderate Downgraded: risk of bias, inconsistency |
All‐cause mortality Pathogen‐reduced platelets vs standard platelets | RR 0.81 [0.5, 1.29] | 6 studies · 1509 participants | Moderate Downgraded: imprecision |
Number of participants with a serious adverse event Pathogen‐reduced platelets vs standard platelets | RR 1.09 [0.88, 1.35] | 7 studies · 1340 participants | Moderate Downgraded: imprecision |
Number of participants experiencing platelet refractoriness Pathogen‐reduced platelets vs standard platelets | RR 2.94 [2.08, 4.16] | 7 studies · 1525 participants | High |
Number of platelet transfusions per participant Multiple platelet transfusion trials Pathogen‐reduced platelets vs standard platelets | no estimate extracted | 6 studies · 1509 participants | High |
Pathogen‐reduced platelets versus standard platelets for the prevention of bleeding in thrombocytopenia
Population: thrombocytopenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants with 'any bleeding' event(s) (WHO grade 1 to 4 or equivalent) ‐ Pathogen‐reduced platelets vs standard platelets | RR 1.09 [1.02, 1.15] | 5 studies · 1085 participants | High |
Number of participants with 'clinically significant' bleeding event(s) (WHO grade ≥ 2 or equivalent) ‐ Pathogen‐reduced platelets vs standard platelets | RR 1.06 [0.93, 1.21] | 4 studies · 983 participants | High |
Number of participants with a 'severe' bleeding event(s) (WHO grade ≥ 3 or equivalent) ‐ Pathogen‐reduced platelets vs standard platelets | RR 1.27 [0.76, 2.12] | 5 studies · 1085 participants | Moderate Downgraded: risk of bias |
All‐cause mortality post‐transfusion Pathogen‐reduced platelets vs standard platelets | RR 0.73 [0.41, 1.29] | 6 studies · 1294 participants | Moderate |
Number of participants with a serious adverse event Pathogen‐reduced platelets vs standard platelets | RR 1.09 [0.88, 1.35] | 5 studies · 1253 participants | Moderate |
Number of patients experiencing platelet refractoriness Pathogen‐reduced platelets vs standard platelets | RR 2.74 [1.84, 4.07] | 6 studies · 1115 participants | High |
Lab response ‐ 24‐hour corrected count increment (CCI) Pathogen‐reduced platelets vs standard platelets | no estimate extracted | 6 studies · 1271 participants | High |